HKPDNasdaqWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends March 31
Cellyan Biotechnology Co., Ltd
Financials through fiscal 2025, year ended Mar 31, 2025Last filing: 20-F on Aug 7, 2026
$0.11+0.00 (+1.81%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Cellyan Biotechnology statistics
Financials through Sep 30, 2025, price as of Oct 19, 2026, median of Wholesale-Drugs, Proprietaries & Druggists' Sundries companies for comparison
Valuation
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Market Cap | $1.83M | $78.64M |
| Enterprise Value | $3.69M | $164.35M |
| PS Ratio | 0.09 | 0.28 |
| PB Ratio | 0.36 | 1.58 |
| P/TBV Ratio | 0.36 | 1.77 |
| P/FCF Ratio | 3.67 | 14.21 |
| P/OCF Ratio | 3.22 | 9.80 |
Enterprise value
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| EV / Sales | 0.18 | 0.40 |
| EV / FCF | 7.39 | 18.61 |
Income (trailing twelve months)
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Revenue | $20.31M | $716.39M |
| Gross Profit | $2.42M | $163.57M |
| Operating Income | -$2.28M | -$30.27K |
| Pretax Income | $36.11K | $413.10K |
| Net Income | -$27.06K | -$63.82K |
| EBITDA | -$2.21M | $2.60M |
| EPS (Diluted) | -$0.00 | $0.02 |
Margins
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Gross Margin | 11.9% | 14.7% |
| Operating Margin | -11.2% | 0.44% |
| Pretax Margin | 0.18% | 0.25% |
| Profit Margin | -0.13% | -0.13% |
| EBITDA Margin | -10.9% | 1.23% |
| FCF Margin | 2.46% | 0.98% |
Returns
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Return on Equity (ROE) | -0.53% | -0.53% |
| Return on Assets (ROA) | -0.28% | -0.67% |
| Return on Invested Capital (ROIC) | -16.3% | 3.04% |
| Return on Capital Employed (ROCE) | -34.6% | 4.42% |
Growth
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 21.7% | 3.83% |
| Net Income Growth (YoY) | -102.0% | -4.31% |
| EPS Growth (YoY) | -101.7% | -3.40% |
Balance sheet
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $190.91K | $9.33M |
| Total Debt | $2.05M | $349.35M |
| Net Cash (Debt) | -$1.85M | -$1.85M |
| Net Cash Per Share | -$0.11 | -$0.06 |
| Equity (Book Value) | $5.14M | $16.46M |
| Book Value Per Share | $0.31 | $0.34 |
| Tangible Book Value | $5.14M | $8.19M |
| Working Capital | $5.83M | $12.53M |
Financial position
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Current Ratio | 2.93 | 1.31 |
| Quick Ratio | 1.75 | 0.55 |
| Debt / Equity | 0.40 | 0.59 |
| Debt / FCF | 4.10 | 4.86 |
| Interest Coverage | -23.39 | 0.82 |
Cash flow (trailing twelve months)
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Operating Cash Flow | $569.21K | $3.55M |
| Capital Expenditures | -$69.92K | -$34.65M |
| Free Cash Flow | $499.30K | $15.14M |
| FCF Per Share | $0.03 | $0.38 |
Efficiency
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Asset Turnover | 2.11 | 1.65 |
| Inventory Turnover | 30.16 | 9.79 |
| Revenue Per Employee | $10.16M | $1.02M |
| Profits Per Employee | -$13.53K | -$8.95K |
| Employee Count | 2 | 559 |
Dividends and yields
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Earnings Yield | -1.47% | -0.31% |
| FCF Yield | 27.2% | 4.46% |
| Buyback Yield | -218.0% | 0.28% |
| Shareholder Yield | -218.0% | 0.83% |
Shares
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Shares Outstanding | 16,350,000 | 32,773,350 |
| Shares Change (YoY) | 38.6% | 0.00% |
| Float | 2,955,030 | 22,533,950 |
| Shares Held by Insiders | 81.9% | 8.34% |
Taxes
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Income Tax | $63.17K | $3.29M |
| Effective Tax Rate | 174.9% | 23.8% |
Scores
| Measure | Cellyan Biotechnology | Industry median |
|---|---|---|
| Altman Z-Score | 2.54 | 3.72 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -2.24 | -2.68 |
Calculated by StockData from Cellyan Biotechnology's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.